SunRegen

Switzerland
Allschwil, Basel-Landschaft, Switzerland, 4123

Company profile

SunRegen company profile

SunRegen is a biopharmaceutical company with a mission to develop drugs to treat neurodegenerative diseases. They focus on innovative treatments for patients suffering from neurological, neuromuscular and ophthalmic diseases. Their first product candidates in development target primary optical atrophy. They are further evaluating them for use in serious neurological / neuromuscular diseases such as ALS, Huntington's, Alzheimer’s and Parkinson’s disease. Their team is composed of passionate and innovative founders and experts who have solid track records in drug development and clinical research in multinational pharmaceutical companies or management experience in international technology enterprises. Their determination in bringing life-changing treatments to patients encompasses everything they do.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2017-01-01, Year

Headquarters

Postal code
4123
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Last funding
Series A / 2019-03-08
Last equity funding
Series A
Investors
2
Founders
2
Articles
4

Founders and investors

Founders

David GuanDong Yuhong

Investors

EISMEAGoBeyond